Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.68 |
| ▸ | PLK1 | P53350 | 6/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | VCP | P55072 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | KMO | O15229 | 2/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734608 | 0.86 | PIK3CG (0.69) | PIK3CAPIK3CBPIK3CGPLK1SYK | |
| SCHEMBL27643199 | 0.85 | PIK3CA (0.74) | PIK3CAPIK3CBPIK3CGPLK1ALOX5 | |
| SCHEMBL14020973 | 0.84 | MAPK8 (0.68) | PIK3CAPIK3CBPIK3CGPLK1AURKA | |
| SCHEMBL4784122 | 0.83 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CGPLK1CLK1 | |
| SCHEMBL4735460 | 0.83 | PLK1 (0.82) | PIK3CAPIK3CBPIK3CGPLK1VCP | |
| SCHEMBL4786087 | 0.81 | PLK1 (0.78) | PLK1VCPSYKAURKACDK4 | |
| SCHEMBL7470875 | 0.79 | PLK1 (0.63) | PIK3CAPIK3CBPIK3CGPLK1VCP | |
| SCHEMBL4737479 | 0.78 | PLK1 (0.61) | PIK3CAPIK3CBPIK3CGPLK1SYK | |
| SCHEMBL4735908 | 0.78 | PIK3CG (0.69) | PIK3CAPIK3CBPIK3CGPLK1CLK1 | |
| SCHEMBL4737520 | 0.77 | PLK1 (0.73) | PIK3CAPIK3CGPLK1SYKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| JP-2007500179-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | PIK3CA 780/4885PIK3CB 1461/4885PIK3CG 1548/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | PIK3CA 4390/4885PIK3CB 4543/4885PIK3CG 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.